GeoVax Labs, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
GOVX Nasdaq 2830 www.geovax.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for GeoVax Labs, Inc.

GeoVax Highlights 2026 as a Pivotal Year for Progress - Jan 20th, 2026 7:00 am
Portal Atlanta at Science Square Grows to Over 30 Member Companies, Marking Major Milestone 15 Months After Launch - Jan 15th, 2026 12:00 pm
GeoVax Announces 1-for-25 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement - Jan 8th, 2026 7:00 am
GeoVax Labs, Inc. to Review Progress and Strategic Priorities During Biotech Showcase 2026 and J.P. Morgan Healthcare Conference Week - Jan 6th, 2026 7:00 am
GeoVax to Raise Approximately $3.2 Million of Gross Proceeds in Public Offering - Dec 19th, 2025 7:24 am
GeoVax Announces Publication of Study Demonstrating Cross-Variant Protection Using the Multi-Antigen GEO-CM04S1 Vaccine - Dec 18th, 2025 11:00 am
GeoVax Receives Formal EMA Scientific Advice Supporting Pivotal Phase 3 Immunobridging Trial for GEO-MVA - Dec 18th, 2025 7:00 am
GeoVax Announces Completion of GEO-MVA Fill-Finish, Supporting Phase 3 Immunobridging Clinical Trial Start-Up in Early 2026 - Dec 17th, 2025 7:00 am
GeoVax Receives U.S. Patent Office Notice of Allowance for Broad-Spectrum COVID-19 Vaccine Design - Dec 16th, 2025 7:00 am
GeoVax Announces British Journal of Haematology Publication Highlighting Superior T-Cell Responses of GEO-CM04S1 in CLL Patients - Dec 15th, 2025 7:00 am
GeoVax Addresses Identification of New Mpox Variant - Dec 11th, 2025 7:00 am
GeoVax Announces Addition of Renowned Global Experts to Its Scientific Advisory Board - Dec 10th, 2025 7:00 am
GeoVax Announces Issuance of U.S. Patent Covering Enhanced Therapeutic Use of Gedeptin(R) Gene Therapy - Dec 9th, 2025 7:00 am
GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin(R) in Recurrent Head & Neck Cancer - Dec 8th, 2025 7:00 am
GeoVax to Present at the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference - Nov 24th, 2025 7:00 am
Geovax Labs Inc (GOVX) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... - Nov 14th, 2025 4:00 pm
GeoVax Reports Third Quarter 2025 Financial Results and Provides Business Update - Nov 13th, 2025 2:00 pm
GeoVax Recognizes World Immunization Day: Advancing Innovation and Trust in Vaccination - Nov 10th, 2025 7:00 am
GeoVax to Report Third Quarter 2025 Financial Results and Provide Corporate Update on November 13, 2025 - Nov 4th, 2025 7:00 am
GeoVax Announces Relocation of Corporate Headquarters and Laboratory Operations to Support Accelerated Growth and Pipeline Advancement - Nov 3rd, 2025 7:00 am